PuraPharm Corporation Limited has released its 2024 Annual Report, detailing the company's business updates and financial performance over the past year. The report includes comprehensive sections such as the Consolidated Statement of Profit or Loss, Consolidated Statement of Comprehensive Income, and Consolidated Statement of Financial Position. The document also provides insights into the company's strategic planning and operations, led by Executive Director Mr. Chan Yu Ling, Abraham. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.